19 Jun 2026

CRC Research Update — June 19, 2026

Creator: The CRC Digest
Published: 2026-06-19T14:33:22Z

Today's colorectal cancer research highlights

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

Mismatch Repair-Deficient Tumors Show Better Survival on Trifluridine/Tipiracil
In a multicenter study of 591 patients with refractory metastatic CRC treated with trifluridine/tipiracil, those with deficient mismatch repair (dMMR) had significantly longer overall survival than those with proficient MMR (median OS 7.8 months overall, p = 0.001 for dMMR vs. pMMR). (Ther Adv Med Oncol)
Digital Outreach Boosts Stool DNA Test Completion in Medicare Beneficiaries
Among Texas Medicare beneficiaries aged 65–85 who received multitarget stool DNA kits, completion rates were higher with digital outreach and varied by payer type and social vulnerability, according to a real-world study of over 10 years of data. (J Health Econ Outcomes Res)
Preoperative Malnutrition Linked to Weakened Immune Response in CRC
A prospective study of 43 colorectal cancer patients found that preoperative malnutrition was associated with suppressed intratumoral T cell function and distinct tumor-associated microbiota, suggesting nutritional status may influence antitumor immunity. (Front Nutr)
Cetuximab Maintenance Therapy Evaluated in Meta-Analysis
A systematic review and meta-analysis assessed the efficacy and safety of cetuximab maintenance therapy in metastatic colorectal cancer, pooling data on progression-free survival, overall survival, and adverse effects through March 2026. (Front Pharmacol)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Prognostic Factors in Young Patients with Liver Metastases
A SEER database study of 2,222 patients with colorectal liver metastases compared disease-specific survival in those under 45 versus 45 and older who underwent colon and liver resection from 2010 to 2021. (J Surg Oncol)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

MiR-31 as Predictive Biomarker for Cetuximab Response
A systematic review evaluated microRNA-31 (miR-31-3p and miR-31-5p) as a potential predictive biomarker for cetuximab efficacy in metastatic CRC, even among RAS wild-type patients where response variability remains high. (Clin Transl Oncol)

Stay informed, stay hopeful — research continues to move forward.

CRC Research Update

Subscribe to The CRC Digest